Skip to main content

AMWA Opposes Judicial Interference in FDA Drug Approval

The American Medical Women’s Association (AMWA) states strong opposition to the Texas court decision in the Alliance for Hippocratic Medicine vs. the Food and Drug Administration (FDA) to suspend approval of mifepristone. This ruling sets a dangerous precedent for judicial interference that undermines FDA’s authority to make evidence-based determinations on the safety and efficacy of medications.  

Contrary to the plaintiffs’ arguments, mifepristone has proven to be a safe method of providing abortion care for more than 20 years as well as an invaluable treatment for miscarriage management and other indications. A lack of access to mifepristone may increase the risk of maternal morbidity and mortality and hinder a physician’s ability to deliver evidence-based standard of care. 

In addition, AMWA has signed on to an Amicus Brief in support of the FDA as the rightful arbiter of mifepristone safety that was filed by our Reproductive Health Coalition co-founding partner, Doctors for America (DFA) ; this was submitted to the appellate court. As an exciting aside, 240 members of Congress also filed a proposed amicus brief on the side of the FDA, seeking to protect access to mifepristone, and cited physician experiences presented in the DFA amicus brief.

Learn more about AMWA’s advocacy efforts.

Close Menu